Morgan Stanley Reports Early Generic Lipitor Risk Explained And Quantified For Pfizer

In a report published by Morgan Stanley, Pfizer's PFE early generic Lipitor risk is explained and quantified. Morgan Stanley said that Mylan filed a lawsuit to compel FDA to act on generic Lipitor. “Mylan believes that FDA should deny Ranbaxy's exclusivity if FDA invoked its Application Integrity Policy against Ranbaxy's Lipitor application. Mylan's lawsuit states that FDA has not responded to repeated requests to discuss the matter, and it is attempting to compel FDA to approve its generic Lipitor in June '11. We estimate $0.11 (5%) downside risk to our 2011E of $2.23 if Mylan succeeds.” Pfizer closed yesterday at $20.18.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorAnalyst RatingsHealth CareMorgan StanleyPfizer Inc.Pharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!